Go Pro

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 1,098 -17.00 (-1.52%)
As of 06:29 AM Eastern

IBT vs. SNN, WWH, FSV, ASHM, and BNKR

Should you buy International Biotechnology stock or one of its competitors? MarketBeat compares International Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with International Biotechnology include Sanne Group (SNN), Worldwide Healthcare (WWH), Fidelity Investment Trust - Fidelity Special Values (FSV), Ashmore Group (ASHM), and The Bankers Investment Trust (BNKR). These companies are all part of the "asset management" industry.

How does International Biotechnology compare to Sanne Group?

International Biotechnology (LON:IBT) and Sanne Group (LON:SNN) are both small-cap asset management industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Sanne Group pays an annual dividend of GBX 0.10 per share. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Sanne Group pays out -2.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, International Biotechnology had 2 more articles in the media than Sanne Group. MarketBeat recorded 2 mentions for International Biotechnology and 0 mentions for Sanne Group. International Biotechnology's average media sentiment score of 0.34 beat Sanne Group's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Neutral
Sanne Group Neutral

6.7% of International Biotechnology shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

International Biotechnology has higher earnings, but lower revenue than Sanne Group. Sanne Group is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.48£37.91M£241.734.54
Sanne Group£194.16M0.00N/A-£4.50N/A

International Biotechnology has a net margin of 82.27% compared to Sanne Group's net margin of 0.00%. International Biotechnology's return on equity of 27.35% beat Sanne Group's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Sanne Group N/A N/A N/A

Summary

International Biotechnology beats Sanne Group on 10 of the 12 factors compared between the two stocks.

How does International Biotechnology compare to Worldwide Healthcare?

Worldwide Healthcare (LON:WWH) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

8.0% of Worldwide Healthcare shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 0.2% of Worldwide Healthcare shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Worldwide Healthcare has a net margin of 85.46% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Worldwide Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Worldwide Healthcare85.46% 8.01% -2.02%
International Biotechnology 82.27%27.35%3.57%

In the previous week, Worldwide Healthcare had 6 more articles in the media than International Biotechnology. MarketBeat recorded 8 mentions for Worldwide Healthcare and 2 mentions for International Biotechnology. Worldwide Healthcare's average media sentiment score of 1.84 beat International Biotechnology's score of 0.34 indicating that Worldwide Healthcare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Worldwide Healthcare
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
International Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Worldwide Healthcare has a beta of 0.5198687, indicating that its share price is 48% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.321, indicating that its share price is 68% less volatile than the broader market.

Worldwide Healthcare pays an annual dividend of GBX 2.40 per share and has a dividend yield of 0.6%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Worldwide Healthcare pays out 9.0% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Worldwide Healthcare has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Worldwide Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Worldwide Healthcare£118.16M11.64£227.88M£26.7014.33
International Biotechnology£78.01M4.48£37.91M£241.734.54

Summary

Worldwide Healthcare beats International Biotechnology on 10 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Fidelity Investment Trust - Fidelity Special Values?

Fidelity Investment Trust - Fidelity Special Values (LON:FSV) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Fidelity Investment Trust - Fidelity Special Values has a net margin of 95.92% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Fidelity Investment Trust - Fidelity Special Values' return on equity.

Company Net Margins Return on Equity Return on Assets
Fidelity Investment Trust - Fidelity Special Values95.92% 25.87% 0.33%
International Biotechnology 82.27%27.35%3.57%

Fidelity Investment Trust - Fidelity Special Values pays an annual dividend of GBX 10.20 per share and has a dividend yield of 2.3%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Fidelity Investment Trust - Fidelity Special Values pays out 9.3% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, International Biotechnology had 1 more articles in the media than Fidelity Investment Trust - Fidelity Special Values. MarketBeat recorded 2 mentions for International Biotechnology and 1 mentions for Fidelity Investment Trust - Fidelity Special Values. Fidelity Investment Trust - Fidelity Special Values' average media sentiment score of 1.69 beat International Biotechnology's score of 0.34 indicating that Fidelity Investment Trust - Fidelity Special Values is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fidelity Investment Trust - Fidelity Special Values
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
International Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fidelity Investment Trust - Fidelity Special Values has higher revenue and earnings than International Biotechnology. Fidelity Investment Trust - Fidelity Special Values is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fidelity Investment Trust - Fidelity Special Values£354.63M4.07£223.72M£109.344.07
International Biotechnology£78.01M4.48£37.91M£241.734.54

12.2% of Fidelity Investment Trust - Fidelity Special Values shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 0.2% of Fidelity Investment Trust - Fidelity Special Values shares are held by company insiders. Comparatively, 1.1% of International Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fidelity Investment Trust - Fidelity Special Values has a beta of 1.2700156, indicating that its share price is 27% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.321, indicating that its share price is 68% less volatile than the broader market.

Summary

International Biotechnology beats Fidelity Investment Trust - Fidelity Special Values on 8 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Ashmore Group?

Ashmore Group (LON:ASHM) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Ashmore Group and Ashmore Group both had 2 articles in the media. Ashmore Group's average media sentiment score of 0.47 beat International Biotechnology's score of 0.34 indicating that Ashmore Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ashmore Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
International Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

International Biotechnology has a net margin of 82.27% compared to Ashmore Group's net margin of 78.55%. International Biotechnology's return on equity of 27.35% beat Ashmore Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Ashmore Group78.55% 14.60% 4.52%
International Biotechnology 82.27%27.35%3.57%

Ashmore Group has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Ashmore Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ashmore Group£135.90M10.16£94.67M£16.5412.84
International Biotechnology£78.01M4.48£37.91M£241.734.54

Ashmore Group currently has a consensus price target of GBX 155, indicating a potential downside of 26.99%. Given Ashmore Group's stronger consensus rating and higher probable upside, analysts plainly believe Ashmore Group is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ashmore Group
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

40.4% of Ashmore Group shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 37.5% of Ashmore Group shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ashmore Group has a beta of 0.962, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.321, suggesting that its stock price is 68% less volatile than the broader market.

Ashmore Group pays an annual dividend of GBX 16.90 per share and has a dividend yield of 8.0%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Ashmore Group pays out 102.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology pays out 13.2% of its earnings in the form of a dividend.

Summary

Ashmore Group beats International Biotechnology on 13 of the 17 factors compared between the two stocks.

How does International Biotechnology compare to The Bankers Investment Trust?

The Bankers Investment Trust (LON:BNKR) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, International Biotechnology had 2 more articles in the media than The Bankers Investment Trust. MarketBeat recorded 2 mentions for International Biotechnology and 0 mentions for The Bankers Investment Trust. International Biotechnology's average media sentiment score of 0.34 beat The Bankers Investment Trust's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
The Bankers Investment Trust Neutral
International Biotechnology Neutral

The Bankers Investment Trust has a net margin of 1,132.30% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat The Bankers Investment Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
The Bankers Investment Trust1,132.30% 22.55% 6.13%
International Biotechnology 82.27%27.35%3.57%

The Bankers Investment Trust has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than The Bankers Investment Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Bankers Investment Trust£322.40M4.20£218.53M£30.134.88
International Biotechnology£78.01M4.48£37.91M£241.734.54

0.5% of The Bankers Investment Trust shares are owned by institutional investors. Comparatively, 6.7% of International Biotechnology shares are owned by institutional investors. 0.0% of The Bankers Investment Trust shares are owned by company insiders. Comparatively, 1.1% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

The Bankers Investment Trust has a beta of 0.618, meaning that its share price is 38% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.321, meaning that its share price is 68% less volatile than the broader market.

The Bankers Investment Trust pays an annual dividend of GBX 2.77 per share and has a dividend yield of 1.9%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. The Bankers Investment Trust pays out 9.2% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

International Biotechnology beats The Bankers Investment Trust on 8 of the 15 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

MetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON Exchange
Market Cap£349.47M£2.49B£6.21B£2.77B
Dividend Yield2.78%6.00%5.24%6.12%
P/E Ratio4.5462.7029.66368.14
Price / Sales4.481,855.001,186.0184,676.43
Price / Cash155.7460.50117.4027.89
Price / Book1.431.326.567.50
Net Income£37.91M£265.96M£1.13B£5.89B
7 Day Performance-2.83%-0.44%-0.21%-0.04%
1 Month Performance13.20%-0.12%0.13%-1.39%
1 Year Performance67.38%7.23%15.05%61.97%

International Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 1,098
-1.5%
N/A+74.2%£349.47M£78.01M4.54N/A
SNN
Sanne Group
N/AN/AN/AN/A£1.50B£194.16MN/A20,100
WWH
Worldwide Healthcare
N/AGBX 390.56
-1.0%
N/A+25.2%£1.42B£118.16M14.63N/A
FSV
Fidelity Investment Trust - Fidelity Special Values
N/AGBX 434.50
+0.8%
N/A+21.0%£1.41B£354.63M3.9725,000
ASHM
Ashmore Group
1.2492 of 5 stars
GBX 213.41
-0.6%
GBX 155
-27.4%
+26.7%£1.40B£135.90M12.90283

Related Companies and Tools


This page (LON:IBT) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners